Harr Steve 4
4 · Sana Biotechnology, Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Sana (SANA) CEO Steve Harr Receives 1.1M RSU Award
What Happened
Steve Harr, President & CEO and a director of Sana Biotechnology (SANA), was granted a total of 1,100,000 restricted stock units (RSUs) on 2026-03-05. The grants reported are: 200,000 RSUs and 900,000 RSUs, each recorded at $0.00 (these are derivative awards, not open-market purchases, so no cash was exchanged at grant).
Key Details
- Transaction date: 2026-03-05; Form 4 filed 2026-03-06 (timely).
- Grants: 200,000 RSUs and 900,000 RSUs; grant price reported as $0.00; total awarded = 1,100,000 RSUs.
- Footnote F1: Each RSU represents a contingent right to one share of Sana common stock.
- Footnote F2: These RSUs vest in four equal annual installments on March 5 of 2027, 2028, 2029 and 2030, subject to continued service.
- Footnote F3: The filing also references an option vesting schedule (25% on March 5, 2027 then monthly over 36 months), but the reported 1.1M units here are RSUs per F1–F2.
- Shares owned after the transaction: not specified in the information provided.
Context
- RSU grants are compensation awards that convert to shares only as they vest; they do not represent immediate cash proceeds or open-market buying/selling.
- Such grants are common for executives and reflect compensation structure rather than a direct market sentiment signal.
- This Form 4 filing appears timely (filed the day after the grant date).
Insider Transaction Report
Form 4
Harr Steve
DirectorPresident & CEO
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-03-05+200,000→ 200,000 total→ Common Stock (200,000 underlying) - Award
Stock Option (Right to Buy)
[F3]2026-03-05+900,000→ 900,000 totalExercise: $3.41Exp: 2036-03-04→ Common Stock (900,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
- [F2]The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
- [F3]The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Signature
/s/ Aaron M. Grossman, Attorney-in-Fact for Steve Harr|2026-03-06